Wall Street heads to court to fend off Biden's regulators
[1/3] The headquarters of the U.S. Securities and Exchange Commission (SEC) are seen in Washington, July 6, 2009. REUTERS/Jim Bourg/File Photo Acquire Licensing Rights WASHINGTON, Nov 21 (Reuters) - Facing a wave of new rules and encouraged by a sympathetic judiciary, U.S. financial firms and…#donaldtrump #apa #tomquaadman #cfpb #mfa #aima #jackinglis #denniskelleher #bettermarkets #trump (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2023 Category: Consumer Health News Source Type: news
Drag Me to Hell, now on Netflix, perfected the lost art of Looney Tunes horror
A little over halfway into Drag Me to Hell, the protagonist is trapped in a tool shed, choking on a throatful of demon. Christine, the sympathetic but nonetheless damned loan officer, is pinned against a bar, about to asphyxiate on this old (undead) woman’s arm. Luckily, Christine’s got an ice…#dragme #daffyduck #samraimis #netflix #raimi #bugsbunny #blackening #acme #looneytunes #evildead (Source: Reuters: Health)
Source: Reuters: Health - November 19, 2023 Category: Consumer Health News Source Type: news
TikTok users posted support for Osama Bin Laden's anti-American propaganda, forcing the service to'aggressively' take down the content as critics circle
Over the past few days, a small group of TikTok influencers shared posts that were sympathetic to Osama Bin Laden, the now deceased Al Qaeda leader who organized the September 11 attacks. The posts referenced Bin Laden’s “Letter to America,” a message he wrote more than 20 years ago justifying the…#tiktok #osamabinladen #alqaeda #binladens #lettertoamerica #israel #middleeast #gaza #binladen #fortune (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2023 Category: Consumer Health News Source Type: news
Children ’s National Hospital spinout ReveraGen BioPharma gearing up for muscular dystrophy drug launch
ReveraGen BioPharma just won FDA approval for a treatment it's been developing for 15 years. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 14, 2023 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news
Psychologically aggressive parenting and later aggression: salivary alpha-amylase reactivity and sex as moderators - Chong LS, Senich KL, Ahmad S, Olezeski CL, Gordis EB.
Psychologically aggressive parenting (PAP) exposure negatively affects children's development of aggression. Nevertheless, not all children exposed to PAP display aggressive behaviors. Sympathetic nervous system (SNS) activity may influence the impact of e... (Source: SafetyLit)
Source: SafetyLit - November 10, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
' Hidden' Cognitive Impairments in DMD May Worsen Outcomes'Hidden' Cognitive Impairments in DMD May Worsen Outcomes
A natural history study that utilized the Pediatric Quality of Life assessment showed that patients with Duchenne muscular dystrophy reported the lowest scores in brain health, including emotional health and school performance.MDedge News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 8, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
How Stress Affects Your Heart Health
For many people, stress is part of everyday life. The demands of work, family, and other quotidian pressures can leave one feeling angry, agitated, anxious, downtrodden, or burned out.
While these kinds of day-to-day challenges are often described as mild forms of stress, the reality is that some people will experience them more often and more significantly than others. And there’s mounting evidence linking these and other forms of stress to heart-related health problems.
[time-brightcove not-tgx=”true”]
“We know from several studies in different populations that emotional and psychological ...
Source: TIME: Health - November 8, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized freelance healthscienceclimate Source Type: news
Government plans to offer support for treatment of rare diseases
"Accordingly, as these patients have already commenced treatment, Sarepta Therapeutics has committed, as per the communication received by the NDRC (National Rare Diseases' Committee), to continue treating these patients with Duchenne muscular dystrophy for the next three months, and to supply the medication free of cost during this period," it said. The court directed doctor Madhulika Kabra from the All India Institute of Medical Science to place the order for the medicine with the company within one week and expedite the procurement for these 14 patients. (Source: The Economic Times)
Source: The Economic Times - November 7, 2023 Category: Consumer Health News Source Type: news
DMD Gene Therapy Safe, Effective at 4 Years DMD Gene Therapy Safe, Effective at 4 Years
Four years after a single dose of SRP-9001 gene therapy, four children with Duchenne muscular dystrophy show sustained stabilization of motor function that would otherwise show expected decline.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 6, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Heart-brain link offers new potential explanation for fainting
Fainting, a temporary loss of consciousness, affects almost 40% of people, yet scientists and physicians don’t know exactly why it happens. A drop in heart rate, blood pressure, and breathing rate—a trio of symptoms long known as the Bezold-Jarisch reflex—can contribute to fainting, researchers have hypothesized. Now, neuroscientists have pinpointed a nerve pathway between the heart and brain that triggers the reflex and can prompt fainting in mice. The findings prove the once-debated reflex exists, and they could one day point toward treatments for fainting in humans.
The study is “an elegant tour de force,...
Source: ScienceNOW - November 1, 2023 Category: Science Source Type: news
Childhood exposure to aggressive parenting and trait anxiety during emerging adulthood: moderating role of autonomic nervous system activity - Chong LS, Senich KL, Olezeski CL, Rabkin AN, Gordis EB.
Exposure to aggressive parenting is a well-established environmental risk factor for anxiety symptoms. Moreover, autonomic nervous system (ANS) activity, including activity in both parasympathetic and sympathetic nervous systems (PNS and SNS), may moderate... (Source: SafetyLit)
Source: SafetyLit - October 31, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Media News - October 31, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Investor Update - October 31, 2023 Category: Pharmaceuticals Source Type: news
Sarepta ’s Duchenne gene therapy fails to meet main goal in key trial
The Cambridge biotech said late Monday that its gene therapy to treat Duchenne muscular dystrophy failed to meet the primary goal of a large Phase 3 trial, but that it plans to seek full approval regardless. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 31, 2023 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
In ‘Killers of the Flower Moon,’ Is Leonardo DiCaprio Playing a Dumb Hick, a Pitiless Sociopath…or a Muddle?
A movie’s central character needn’t be someone we admire, but he should probably be someone we’re drawn to, someone we vibe with in sympathetic fascination, who we feel we know and understand even as he crosses over to the dark side. Few movies have lived out that dynamic more cathartically than…#martinscorsese #meanstreets #scorsese #harveykeitels #robertdeniros #johnnyboy #deniros #travisbickle #goodfellas #rayliotta (Source: Reuters: Health)
Source: Reuters: Health - October 29, 2023 Category: Consumer Health News Source Type: news
